Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hypoxia-inducible factor 2-alpha (HIF-2α) promoter G-quadruplex is a non-canonical DNA secondary structure located within the guanine-rich regulatory region of the EPAS1 gene [1.2.1]. This structure consists of stacked guanine tetrads stabilized by Hoogsteen hydrogen bonding and monovalent cations, serving as a critical molecular switch for transcriptional control [1.2.3, 1.2.5]. In oncogenic contexts, particularly in clear cell renal cell carcinoma (ccRCC) and neuroblastoma, HIF-2α is frequently overexpressed, driving angiogenesis, metabolism, and cell survival [1.2.1, 1.3.2]. The G-quadruplex structure in its promoter acts as a transcriptional silencer; when stabilized by small-molecule ligands, it physically obstructs the assembly of the transcription initiation complex and the binding of activating transcription factors such as Sp1 [1.2.1, 1.4.2]. Consequently, targeting this structure with G-quadruplex-stabilizing drugs like CL67 or TMPyP4 offers a therapeutic strategy to downregulate HIF-2α expression at the genomic level [1.2.1, 1.4.3]. This approach is particularly relevant for treating cancers that are resistant to traditional therapies or where the HIF-2α protein itself is difficult to inhibit directly [1.2.1, 1.4.1].
Stabilization of the G-quadruplex structure within the promoter region of the EPAS1 gene, which inhibits the binding of transcription factors (e.g., Sp1, AP2) and the assembly of the RNA polymerase II complex, thereby repressing the transcription of HIF-2α [1.2.1, 1.4.3].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxia-inducible factor 2-alpha (HIF-2α) promoter G-quadruplex (HIF-2α promoter G4).